Open AccessErratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’
Author(s) -
Sebastian Ochsenreither,
Walter Fiedler,
G. Del Conte,
Marina Macchini,
Ignacio Matos,
Beate Habel,
I. Ahrens-Fath,
Francesco Raspagliesi,
Domenica Lorusso,
Ulrich Keilholz,
Christina C. Rolling,
Maxim Kebenko,
Konrad Klinghammer,
Omar Saavedra,
Harald Baumeister,
Alfredo Zurlo,
Elena Garralda
Publication year - 2022
Publication title -
esmo open
Language(s) - English
Resource type - Journals
ISSN - 2059-7029
DOI - 10.1016/j.esmoop.2022.100549
Subject(s) - muc1 , refractory (planetary science) , monoclonal antibody , tolerability , solid tumor , antibody , epitope , epidermal growth factor receptor , cancer research , medicine , oncology , pharmacology , biology , receptor , immunology , adverse effect , immunohistochemistry , cancer , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom